Your LDL looks fine. That doesn't mean you're in the clear.

YOUR HEALTH — Issue No. 17

The cardiovascular conversation continues. Plain Medicine covers it plainly.

Over the last three weeks we have covered cardiovascular risk, the medications that reduce it, and the role sleep plays in it. Each of those issues started from the same place — the standard tools most patients and providers rely on to assess cardiovascular health.

This week we need to talk about one of those tools falling short.

Your standard lipid panel gives you four numbers: total cholesterol, LDL, HDL, and triglycerides. Most cardiovascular risk conversations start and end there. LDL is the primary target. If it looks good, the assumption is that the lipid picture is under control.

That assumption is wrong for approximately 20% of people. And for those people — the ones whose LDL looks fine while their true cardiovascular risk is significantly elevated — a single additional blood test would tell a completely different story.

That test measures ApoB. And most patients have never heard of it.

What a lipoprotein actually is

Before we can understand ApoB, we need to understand what cholesterol actually travels in — because this is where the standard lipid panel starts to mislead.

Cholesterol does not float freely in the bloodstream. It cannot — fat and water don't mix. Instead, cholesterol is packaged inside protein-coated particles called lipoproteins. These particles are the vehicles that carry cholesterol through circulation. The most important ones for cardiovascular risk are LDL particles — which carry cholesterol from the liver to the body's tissues.

Here is the key distinction that most standard cholesterol testing misses:

LDL cholesterol — what your lab report calls LDL-C — measures the total mass of cholesterol inside LDL particles. It tells you how much cholesterol is being carried.

ApoB — counts how many atherogenic particles are actually in circulation. Each LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB molecule. One ApoB equals one atherogenic particle. It tells you how many vehicles are on the road — not just how much cargo they are carrying.

These two things are not the same. And the difference between them is where cardiovascular risk can hide.

When LDL lies to you — the discordance problem

Here is the clinical problem in plain terms.

When triglycerides are elevated, LDL particles tend to become smaller and more cholesterol-depleted. Two patients can have identical LDL cholesterol readings while carrying very different numbers of atherogenic particles. The standard panel sees the same number. The cardiovascular risk is not the same.

This is called discordance — when LDL cholesterol and particle number point in different directions. It occurs most commonly in patients with insulin resistance, type 2 diabetes, high triglycerides, or metabolic syndrome. It is not rare. It affects approximately 20% of people.

What discordance looks like in real life:

LDL-C: 72 · Triglycerides: 240 · HDL: 39 · ApoB: 112

The LDL doesn't look alarming. The ApoB tells a completely different story.

Pearl to remember:

High triglycerides + diabetes or insulin resistance + "okay" LDL = think ApoB.

The statin patient who thinks they're covered

This is the clinical scenario that matters most for Plain Medicine readers already on a statin. A patient comes in for follow-up. Their LDL is 58. They say: "My LDL is great, so I'm good, right?"

Maybe. But maybe not.

The 2026 AHA/ACC dyslipidemia guidelines specifically identify ApoB as useful in exactly this situation — once LDL and non-HDL goals appear to have been achieved, but residual risk may remain. Particularly in patients with triglycerides above 200, diabetes, or metabolic syndrome — even a well-controlled LDL can coexist with an elevated ApoB. The statin lowered the cholesterol mass. It may not have fully addressed the particle burden.

This is one reason the guidelines now formally recommend ApoB measurement for adults on lipid-lowering therapy. The patient who believes they are covered because their LDL looks good may be exactly the patient who benefits most from knowing their ApoB.

Particle size — the Velcro problem

Not all LDL particles are created equal. Beyond particle number, size matters — and smaller is more dangerous.

Large, buoyant LDL particles are relatively benign. They are too large to easily penetrate the endothelial lining of arterial walls.

Small, dense LDL particles are a different story. They are small enough to slip through more easily. Once inside the arterial wall, they oxidize more readily — and oxidized LDL is what triggers the inflammatory cascade that builds plaque. Small dense LDL particles also have a higher affinity for arterial wall components — they grab on and stay. Think of large LDL particles as smooth balls bouncing off a wall. Think of small dense LDL particles as Velcro.

What drives small dense LDL production? Insulin resistance and metabolic syndrome are the strongest drivers. Triglycerides above 150 mg/dL consistently correlate with smaller, denser particle distribution. Refined carbohydrate intake, physical inactivity, and excess body weight all push the liver toward producing more small dense LDL.

The clinical implication: a patient with type 2 diabetes, pre-diabetes, or metabolic syndrome and a seemingly normal LDL may have a far more dangerous lipid profile than their standard panel suggests.

Why your provider probably isn't checking it

This has nothing to do with clinical judgment. It is a coverage problem.

ApoB is not covered by most major insurance plans as a routine screening test. Medicare does not cover it for routine screening either. The standard lipid panel is what insurance covers at a wellness visit. So that is what gets ordered.

I'll be honest — I don't order ApoB as often as I probably should in my own practice. My patient panel skews toward Medicare, which doesn't cover it for routine screening. In a 20-minute wellness visit, ordering an out-of-pocket test requires a separate conversation that isn't always easy to have. I use clinical judgment — triglycerides, metabolic status, family history, diabetes — to guide treatment decisions without it.

But the test exists. It is inexpensive. And the 2026 guidelines are now clear about when it adds information. If you fall into the categories above — bring it up. Your provider will know exactly what to do with the number.

ApoB is available as a cash-pay test through direct-to-consumer ordering services that use LabCorp or Quest reference labs. Prices run approximately $28 to $65 depending on the platform and location — confirm before ordering as pricing varies. Despite the 2026 guideline recommendation, less than 1% of insured adults get their ApoB tested each year. The test exists. Most people just don't know to ask for it.

When LDL is controlled but ApoB remains elevated

If you are on a statin and your LDL looks good but your ApoB remains elevated — here are the options in order of typical clinical escalation:

Intensify statin therapy — if not already on a high-intensity statin (atorvastatin 40-80mg or rosuvastatin 20-40mg), stepping up can reduce ApoB by an additional 10-20%.

Add ezetimibe (Zetia) — covered in Issue #14. Inexpensive, well tolerated, and adds approximately 15-20% additional ApoB reduction on top of statin therapy. Often the most practical next step.

Lower triglycerides — elevated triglycerides drive VLDL particle production which directly raises ApoB. Reducing triglycerides through dietary changes — particularly reducing refined carbohydrates and added sugars — weight management, and regular exercise reduces ApoB by reducing the number of particles the liver produces. Prescription omega-3 therapy is an option in some patients — discuss with your provider. Standard over-the-counter fish oil supplements are not equivalent to prescription-strength omega-3 medications and do not carry the same cardiovascular outcomes evidence.

PCSK9 inhibitors (Repatha)— reduce ApoB by an additional 50-60% on top of statin therapy. The most powerful option available — but insurance approval typically requires documented statin intolerance or established cardiovascular disease. Not easily accessible for most primary prevention patients.

How often should ApoB be rechecked?

If you are starting or adjusting lipid-lowering therapy — recheck ApoB approximately 3 months after the change. Statins and ezetimibe reach steady-state effect within 4 to 6 weeks — waiting 3 months gives the medication time to work and avoids testing before the full effect is established.

Once ApoB is at target on a stable regimen — annual monitoring is sufficient for most patients. ApoB is more stable than triglycerides and does not fluctuate significantly from day to day. Frequent retesting beyond annual monitoring adds cost without meaningful additional information.

Something worth saying plainly:

LDL tells you how much cholesterol is in the particles.

ApoB tells you how many atherogenic particles are out there.

Those are different questions. For most people the answers point in the same direction. For approximately 20% — particularly those with diabetes, high triglycerides, metabolic syndrome, or established cardiovascular disease — they don't.

ApoB is not a replacement for your standard lipid panel. It is an additional piece of information that can sharpen the picture when the standard panel leaves questions unanswered.

A normal ApoB is reassuring — but it is not a reason to stop a statin. The decision about statin therapy involves your full cardiovascular risk picture, not any single number.

The Member deep-dive this week goes further — non-HDL cholesterol as a practical ApoB surrogate, the Lp(a) and ApoB relationship, how to interpret your number in context, and what to do when ApoB remains elevated despite a well-controlled LDL on statin therapy.

Next week: The Forgotten — the critical follow-up items that fall through the cracks between your EMR and your next appointment.

Plain Medicine is published for educational purposes only and does not constitute medical advice or establish a patient-provider relationship. Always consult your healthcare provider before making medical decisions.

— Kyle